Country of origin - France
Pharm-Group - Products for the treatment and prevention of prostate diseases
Manufacturers - GlaxoSmithKline/RP Scherer (France)
International name - Dutasteride
Dosage forms - capsules 0.5 mg
Composition - Active substance - dutasteride.
Indications for use - Treatment and prevention of benign prostatic hyperplasia (reduces its size, improves urination and reduces the risk of acute urinary retention and the need for surgical treatment).
Contraindications - Hypersensitivity to dutasteride, other 5a-reductase inhibitors or to any ingredient of the drug. Dutasteride is contraindicated in women and children.
Side effects - Impotence, decreased libido, impaired ejaculation, gynecomastia (includes soreness and enlargement of the mammary glands), allergic reactions (skin rash, itching, urticaria, localized swelling).
Interaction - CYP3A4 inhibitors may increase plasma concentrations of dutasteride. CYP3A4 inhibitors (verapamil and diltiazem) reduce the clearance of dutasteride. The decrease in clearance of dutasteride and the subsequent increase in its concentration in the blood, when used simultaneously with CYP3A4 inhibitors, is not clinically significant (no need to reduce the dose).
Overdose - No data available.
Special instructions - Dutasteride is absorbed through the skin, so women and children should avoid contact with damaged capsules. In case of contact with damaged capsules, immediately wash the affected area of skin with soap and water. Effect on the detection of prostate-specific antigen and prostate cancer. In patients with benign prostatic hyperplasia, it is necessary to carry out the necessary examinations of the prostate gland before starting and periodically during treatment to exclude the development of prostate cancer. Taking dutasteride does not affect driving or operating machinery.
L